Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics and Celera today announced they have signed a definitive agreement for the purchase of Celera by Quest for $671 million, or $344 million net of cash and short-term investments.

Quest will pay $8 for each share of Celera. The deal includes $327 million in acquired cash and short-term investments.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.

The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.

Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.

In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.